Health And Pharma
Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report …
FDA Approves Sotorasib and Panitumumab Combination: …
1 day ago · The U.S. FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS G12C-mutated metastatic …
FDA Approves Innovative ADC Datroway for Unresectable or …
8 hours ago · The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer. This …
FDA Approves 225Ac-SSO110 Radiopharmaceutical Trial for Small …
4 days ago · About Ariceum and Satoreotide. Ariceum’s lead targeted systemic radiopharmaceutical candidate, SSO110 (“satoreotide”) labelled with Lutetium-177 (177Lu) …
Regulatory Approval Boosts Pelareorep’s Innovative Oncolytic …
2 days ago · Oncolytics Biotech received approval from Germany\u2019s Paul-Ehrlich-Institute to advance Cohort 5 of the GOBLET study, evaluating pelareorep with mFOLFIRINOX, with or …
Dr. Rafael Rosell Discusses the Efficacy of KRAS G12C Inhibitor in …
1 day ago · Dr. Rafael Rosell, principal investigator of the KROCUS study, discusses advancements in the treatment of non-small cell lung cancer with the KRAS G12C mutation in …
ONCOLife | Health And Medicine
About ONCOLife. ONCOLife as a cutting-edge oncology magazine designed for oncologists and health professionals. It has flexible format, available both in print and online formats in the US …
Posts | Health And Medicine
Dec 21, 2024 · Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma …
About Us - Health And Pharma
Health & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report …
Olaparib Shows Long-term Survival Benefits in BRCA+ and HER2
Dec 13, 2024 · A Transformative Option in Early-Stage Disease. When first announced in 2022, the OlympiA findings led to regulatory approval of olaparib in the adjuvant (post-surgery) …